490 related articles for article (PubMed ID: 12738716)
21. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
24. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
Hajjar G; Sharkey RM; Burton J; Zhang CH; Yeldell D; Matthies A; Alavi A; Losman MJ; Brenner A; Goldenberg DM
Clin Colorectal Cancer; 2002 May; 2(1):31-42. PubMed ID: 12453334
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer.
Hahm HA; Ettinger DS; Bowling K; Hoker B; Chen TL; Zabelina Y; Casero RA
Clin Cancer Res; 2002 Mar; 8(3):684-90. PubMed ID: 11895896
[TBL] [Abstract][Full Text] [Related]
27. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
28. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
Welt S; Ritter G; Williams C; Cohen LS; Jungbluth A; Richards EA; Old LJ; Kemeny NE
Clin Cancer Res; 2003 Apr; 9(4):1347-53. PubMed ID: 12684403
[TBL] [Abstract][Full Text] [Related]
29. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
32. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
33. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
38. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
[TBL] [Abstract][Full Text] [Related]
39. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]